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Abstract
Background: The number of people with dementia is increasing alongside the aging population, and most of these
patients manifest with neuropsychiatric symptoms (NPS). The objective of this study was to investigate anti-dementia
drug use and its associations with NPS.
Methods: Questionnaires on demographic information, current drug use, activities of daily living and NPS were sent to
all municipal home care producers and to all institutions providing long-term residential care in the South Savo
Hospital District, Finland.
Results: The study population comprised 2821 persons. Their mean age was 81 years and 68 % were female.
Dementia had been diagnosed in 31 % (n = 410) in home care and in 56 % (n = 774) in residential care. Anti-dementia
drugs were used by 69 % of patients with dementia. Hyperactivity symptoms were common in residential care patients
(n = 456, 33 %), while problems with mood and apathy dominated in home care patients (n = 486, 54 %). In
multivariate regression analysis, the mood symptoms and apathy subgroup was associated with use of an
acetylcholinesterase inhibitor (AChEI) (OR 1.44; 95 % Cl 1.03–2.02), memantine (OR 1.77, 95 % Cl 1.15–2.72) or their
combinations (OR 1.56, 95 % Cl 1.03-2.34). Hyperactivity symptoms were associated with combination therapy of this
type (OR 2.03, 95 % Cl 1.36–2.34).
Conclusions: The use of anti-dementia drugs was common in both care settings. The use of any anti-dementia drug
or combination was associated with the mood and apathy subgroup. The hyperactivity subgroup was associated with
combination use of memantine and AChEI.
Background
Dementia contributes one-tenth of the years spent with
disability in people aged over 60 years. This is more than
the proportion of stroke, cardiovascular disease or can-
cer [1]. An estimated 42.3 million people globally will
suffer from dementia by the year 2020 and over 80 mil-
lion by 2040 [1], not only in high-income but also low-
and middle-income countries [2]. The annual costs of
dementia are estimated to be 600 billion US dollars [3].
Neuropsychiatric symptoms (NPS) occur in 80–90 % of
persons with dementia [4]. They may be more disruptive
to patients and their caregivers than the decline of cog-
nition [5]. NPS are associated with decline in global
functioning, increased use of medications and frequent
hospitalization [6]. Agitation, aggression and psychosis
are the most distressing NPS and correlate with early
transfer to institutional care [7].
Many attempts have been made to form subgroups or
symptom clusters of NPS [8–12]. In a large multicenter
study with 2 354 outpatients with Alzheimer’s disease,
four NPS subgroups were found: hyperactivity, psych-
osis, affective symptoms and apathy [13]. Petrovics and
co-workers identified four factors based on the Neuro-
psychiatric Inventory (NPI) [14], namely psychosis fac-
tor, psychomotor factor, mood liability factor and
instinctual factor [10]. Most studies agree that NPS form
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three to five subsyndromes consisting of hyperactivity
symptoms, mood symptoms, psychotic symptoms and
apathy [12, 13].
Anti-dementia drugs are used not only to improve
cognitive functions but also to treat behavioral symp-
toms [15]. They are either AChEIs (donepezil, rivastig-
mine and galantamine) or memantine. AChEIs are
recommended for use in mild to moderate dementia and
to reduce NPS, and memantine in moderate to severe
dementia and to diminish behavioral symptoms [16].
The concomitant use of memantine and AChEI is not
recommended by NICE 2011, although there may be a
small benefit on NPS at six months after the initiation of
treatment [17]. Most studies exploring the effect of anti-
dementia drugs on NPS have been primarily designed to
evaluate their effect on cognition [18]. The effect on
NPS may be limited [19].
As the number of people with dementia is increasing
and most of these patients manifest with NPS, the aim
of this study was to investigate the use of anti-dementia
drugs and the prevalence of NPS in two different popu-
lations and the associations between anti-dementia drug
use and NPS.
Methods
Study design and participants
We identified with the help of local and regional author-
ities all public home care units (n = 21) providing regular
care (a nurse visiting a home-dwelling patient at least
once a week) and all institutions (n = 68) giving long-
term residential care to older people, including both pri-
vate and municipal residential care facilities, nursing
homes and long-term wards in municipal hospitals. The
catchment area of the South Savo Hospital District is
105 000 inhabitants [20]. Due to strong support from
the local authorities, we had an excellent response rate.
Twenty out of 21 municipal home care units responded,
and 66 out of 68 residential care units responded
(Fig. 1).
General information about the study and the question-
naires were mailed to the nurses and doctors in charge
who were responsible for instructing the nurses on the
field. Written instructions on how to carry out the as-
sessments were included, and the staff were given the
name and telephone number of the first writer if add-
itional guidance was needed. The study was carried out
in May 2011.
Study population (South Savo Hospital District) 
21 public home care units 
(providing regular home-care)
68 institutions
(giving long-term residential care)
20 home care units responded 
n=1382
66 institutions responded 
n=1439
2 refused




Dementia not diagnosed n=1518 
Missing data n=119
Users of anti-dementia drugs
n=791
Missing data n=42
Non-users of anti-dementia drugs
n=351
1 refused 
Fig. 1 Flowchart of the study
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Questionnaires
The basic demographic information of each patient, e.g.
municipality, service unit or residential care unit, age
and sex, was followed by questions concerning current
regularly used medications, which were obtained from
electronic medical records. Activities of daily living
(ADL) were assessed by the Barthel Index (scale 0–100)
[21]. On this scale, the higher the score, the better the
functioning. Cognitive functioning was assessed in two
ways. Firstly, we inquired about the results of the latest
Mini Mental State Examination (MMSE, scale 0–30)
[22] if carried out in 2010 or 2011. Cognition had been
assessed by MMSE in 743 patients (51.6 %) in residential
care and in 627 patients (45.2 %) in home care services.
Nurses reported whether dementia had been diagnosed
by a physician, but we did not sort out different demen-
tia types. Secondly, we asked the nurse to assess each
patient’s memory by direct observation and assign it to
one of four categories by the clinical dementia rating
(normal, slightly impaired, moderately impaired, or se-
verely impaired) [23]. We did not ask the dates of de-
mentia diagnosis, start of the anti-dementia drugs or the
beginning of NPS.
Each patient was evaluated by a nurse who knew the
patient, and NPS were listed according to a symptom list
based on the Neuropsychiatric Inventory (NPI). The
scale was originally developed to assess behavioral and
psychological symptoms in dementia and it consists of
12 items, each of which is scored for frequency and se-
verity. Nurses reported all NPS of each patient during
the preceding week in home care (due to visiting proce-
dures at least once a week in home care) and during the
preceding 24 h in residential care (observation and care
available 24/7). The assessment gave only the presence
or absence of the symptom, not the severity or the ef-
fects on carers. The interrater reliability was not
assessed, but the nurses had written instructions to
evaluate the symptoms. We organized the NPS into
three subgroups [8]: 1) hyperactivity consisting of agita-
tion or aggression, disinhibition, irritability and aberrant
motor behaviour, 2) psychosis consisting of delusions
and hallucinations, and 3) mood symptoms and apathy
consisting of depression, anxiety, sleeping disturbances,
eating disturbances, apathy and euphoria. Fifty-three pa-
tients in home care and 89 patients in residential care
had no data concerning NPS. These 142 patients were
excluded from all NPS or subgroup analyses.
Classification of medication
Drugs were classified according to the Anatomical Thera-
peutic Chemical (ATC) classification of medicines recom-
mended by the World Health Organization (WHO) [24].
The anti-dementia drugs included memantine (N06DX01)
and the AchEIs: (N06D) donepezil (N06DA02), rivastig-
mine (N06DA03) and galantamine (N06DA04).
Ethics
The study design was accepted by the Ethics Committee
of the South Savo Hospital District. The use of current
medication was obtained from medical records, without
identification of individual patients. Other data were ob-
tained from a special questionnaire form, which was sent
to the institutions and home care services. Informed
consents were not needed in our study, because data did
not contain birth dates or other material by which a per-
son could have been identified. In addition, ad hoc ques-
tionnaire did not include other identification than
municipality, service unit or residential care unit, age
and gender. As participation in the study was supported
by local health authorities, no incentives were needed to
promote the response rate.
Data analysis
Differences in characteristics of patients by setting,
prevalence and number of NPS among users of anti-
dementia drugs were described using proportions
and means with standard deviation (SD). Statistical
comparisons between groups were conducted using
Chi-square test and independent samples t-test or one-way
analysis of variance, with p ≤ 0.05 considered significant.
Univariate and multivariate (stepwise, forward selection)
regression analyses were performed to identify demo-
graphic (age, sex and home care/residential care) and
neuropsychiatric subgroups (hyperactivity, psychotic symp-
toms, mood symptoms and apathy) associated with anti-
dementia drug use. Results were expressed as odds ratios
(ORs) with corresponding 95 % confidence intervals (95 %
CIs). In the Tables 3 and 4 the missing p-values of NP were
due to confidentiality matters. Data were analyzed using
SPSS 19.0 software.
Results
The study population comprised 2821 persons, 68.1 %
(n = 1921) of whom were women (Table 1). The mean
age of participants was 80.9 (SD 10.1) years, 82.0 (SD
9.8) years in residential care and 79.8 (SD 10.4) years in
home care. Only 8 % (n = 224) were younger than
65 years. Of home care patients, 81 % lived alone. De-
mentia had been physician-diagnosed in 1184 patients
(43.8 %), 56.0 % in residential care and 31.1 % in home
care. ADL were worse in residential care (mean Barthel
Index 36.9, SD 30.8) than in home care (mean 80.8, SD
20.9, p < 0.001). Bedridden persons constituted 0.9 % of
patients in home care, and 15.4 % in residential care.
Anti-dementia drugs were used by 31.9 % (n = 901) of
the study population. AChEIs were used by 19.3 % of pa-
tients and memantine by 8.7 % of residential care and
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3 % of home care patients. Combination therapy with
AChEI and memantine was used by 9.0 % of residential
care and 4.4 % of home care patients.
Neuropsychiatric symptoms
More than half of the patients in both settings suffered
from NPS (Table 2). In residential care 19.1 % and in
home care 15.1 % of patients suffered from two to three
simultaneous NPS, and 5.7 % and 4.5 % suffered from at
least four symptoms, respectively. The most common
NPS subgroup was mood symptoms and apathy (n = 908).
Hyperactivity subgroup symptoms occurred in 684 pa-
tients and psychotic symptoms in 278 patients. In residen-
tial care, the most common subgroup was hyperactivity
(32.9 %), while in home care mood symptoms and apathy
predominated (54.4 %). The most common distinct symp-
toms were agitation/aggression, irritability and depression
in residential care, but depression, sleeping problems and
irritability in home care. Disinhibition was seldom seen
(2.0 %) in home care, whereas it was reported in almost
one-tenth (8.9 %) of patients in residential care.
Patients with diagnosed dementia
Of persons with diagnosed dementia (n = 1142),
altogether 66.8 % (n = 791) used anti-dementia drugs
(Table 3). Of these 58.8 % used AChEIs, 18.3 % meman-
tine and 22.9 % combinations of an AChEI and meman-
tine. Users of anti-dementia drugs had higher mean
ADL (58.0 vs. 29.8) and MMSE score (16.0 vs.14.7) than
non-users. The prevalence of NPS was about the same
in both groups.
The frequency of NPS did not differ between the three
groups studied: users of AChEI only, memantine only or
combination of both (Table 4). In multivariate analyses,
any kind of anti-dementia drug use appeared to be inde-
pendently associated with the subgroup of mood symp-
toms and apathy, and the use of a combination therapy
was associated with hyperactivity but not with psychotic
symptoms (Table 5). The ADL score was associated with
Table 1 Characteristics, functioning and anti-dementia drug use of patients by setting
Total Residential care Home care P- value
(n = 2821) (n = 1439) (n = 1382)
Characteristics
Female, n (%) 1921 (68.1) 995 (69.1) 926 (67.0) 0.223
Mean age, years (SD) 80.9 (10.1) 82.0 (9.8) 79.8 (10.4) <0.001
≤ 64, n (%) 224 (8.0) 89 (6.2) 135 (10.6)
65-74, n (%) 354 (12.6) 172 (11.0) 182 (12.5)
75-84, n (%) 1056 (37.6) 511 (35.6) 545 (39.7)
≥ 85, n (%) 1174 (41.8) 664 (46.2) 513 (37.2)
Diagnosis and functioning
Diagnosed dementia, n (%) 1184 (43.8) 774 (56.0) 410 (31.1) <0.001
ADL score (%, SD) 58.4 (34.3) 36.9 (30.8) 80.8 (20.9) <0.001
Bedridden, n (%) 233 (8.3) 221 (15.4) 12 (0.9) <0.001
Drug use
Total number of drugs, mean (SD) 8.6 (4.7) 8.5 (4.2) 8.5 (5.3) 0.437
Anti-dementia drug users, n (%) 901 (31.9) 516 (35.9) 385 (27.9) 0.007
AChEI alone, n (%) 545 (19.3) 262 (18.2) 283 (20.5) 0.015
Donepezil, n (%) 291 (10.3) 127 (8.8) 161 (11.6)
Rivastigmine, n (%) 153 (5.4) 99 (6.9) 54 (3.9)
Galantamine, n (%) 107 (3.8) 36 (2.5) 69 (4.9)
Memantine alone, n (%) 166 (5.8) 125 (8.7) 41 (3.0) 0.003
AChEI and memantine 190 (6.7) 129 (9.0) 61 (4.4) <0.001
Donepezil + memantine, n (%) 94 (3.3) 60 (4.2) 34 (2.5)
Rivastigmine +memantine, n (%) 63 (2.2) 51 (3.5) 12 (0.9)
Galantamine +memantine, n (%) 33 (1.2) 18 (1.3) 15 (1.1)
Chi-square test for categorical variables and Student’s t-test for continuous variables
ADL score = Barthel Index, scale 0–100
AChEI Acetylcholinesterase inhibitor
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any kind of anti-dementia drug use, and age was asso-
ciated with use of either an AChEI or memantine, but
not with their combination.
Discussion
In our large, geographically defined study population,
the use of any anti-dementia drug was associated with
the NPS subgroup of mood symptoms and apathy. In
addition, hyperactivity subgroup symptoms were associ-
ated with the combination therapy of AChEI and mem-
antine. Psychotic symptoms were not associated with the
use of AChEIs, memantine or their combinations. To
our knowledge, this is the only study investigating the
associations between anti-dementia drug use and preva-
lence of NPS subgroups. Mood symptoms and apathy
were the most common NPS in anti-dementia drug
users. According to previous studies, anti-dementia
drugs improve depressive symptoms in mild to moderate
dementia, independent of any effect on cognition [25]. A
Swedish study [26] reported no association between
depressive symptoms and the use of anti-dementia
drugs. Instead, they found an association between anti-
dementia drug use and aggressive behaviour. The
efficacy of AChEIs in the management of NPS in Alzhei-
mer’s disease is limited [14]. Despite, anti-dementia
drugs are recommended as a first-line pharmacological
treatment for NPS just after non-pharmacological inter-
ventions [20]. In Finland, the National Treatment Guide-
lines recommend the use of AChEIs to treat NPS in
patients with dementia [16].
Combination therapy of memantine and AChEI has
growing evidence of efficacy in cognitive decline [27, 28],
but the effect on NPS is controversial [29]. However,
memantine alone has had some effect on hyperactivity
symptoms [7]. Psychotic symptoms occurred in every
tenth patient in our study. Although memantine has been
found to have some benefits in treating psychotic symp-
toms [30] without an increased risk of mortality, which
occurs with anti-psychotics [31], we found no association
between the use of any anti-dementia medication and the
psychosis subgroup. Persons with psychotic symptoms
may have been treated with anti-psychotic drugs rather
than with anti-dementia drugs. This may be due to evi-
dence that risperidone, olanzapine and aripiprazole are su-
perior to placebo in treating agitation and psychosis in
dementia [32].
The use of anti-dementia drugs has increased in the
last few years [33], and the proportion of AChEI users in
long-term residential care varies from 3 % in Australia
Table 2 Frequency of NPS (n, %) and subgroups in patients by
setting
Residential care Home care P-value
n = 1386 (%) n= 1293 (%)
Frequency of NPS
None 643 (46.4) 642 (49.7) 0.014
One symptom 398 (28.7) 397 (30.7) 0.357
Two to three symptoms 265 (19.1) 195 (15.1) 0.002
Four or more symptoms 79 (5.7) 58 (4.5) 0.110
Subgroups
Hyperactivitya 456 (32.9) 228 (17.6) <0.001
Agitation/aggression 224 (16.1) 92 (7.1)
Disinhibition 123 (8.9) 26 (2.0)
Irritability 220 (15.9) 144 (11.1)
Aberrant motor behaviour 83 (6.0) 21 (1.6)
Psychosisa 146 (10.6) 132 (10.2) 0.788
Delusions 72 (5.2) 76 (5.9)
Hallucinations 93 (6.7) 77 (6.0)
Mood symptoms and apathya 422 (30.5) 486 (54.4) <0.001
Depression 157 (11.3) 271 (21.0)
Anxiety 115 (8.3) 101 (7.8)
Sleeping problems 130 (9.4) 179 (13.8)
Eating problems 75 (5.4) 70 (5.4)
Elation 20 (1.4) 18 (1.4)
Apathy 69 (5.0) 40 (3.1)
NPS Neuropsychiatric symptoms
aOne person could suffer from several symptoms, thus total number of cases
in the subgroups is not the same as the total number of patients suffering
from at least one neuropsychiatric symptom (NPS). Missing cases: 53 in
residential care and 89 in home care
Table 3 Frequency of NPS and subgroups, ADL functioning and






n = 791 n = 351
Frequency of NPS, n (%)
None 320 (40.4) 162 (46.1) 0.074
One symptom 252 (31.8) 114 (32.5) 0.867
Two to three
symptoms
171 (21.6) 55 (15.7) 0.016
Four or more
symptoms
48 (6.1) 20 (5.7) 0.771
Any NPS, n (%) 471 (59.5) 189 (53.8) 0.771
Subgroups, n (%)
Hyperactivity 264 (33.3) 116 (33.0)
Psychosis 105 (13.2) 36 (10.3)
Mood symptoms and
apathy
299 (37.6) 90 (25.6)
ADL score, mean (SD) 58.0 (31.5) 29.8 (34.5) <0.001
MMSE, mean (SD) 16.0 (6.6) 14.7 (8.0) 0.011
ADL = Barthel Index, scale 0–100
NPS Neuropsychiatric symptoms, MMSE Mini Mental State Examination
*Chi-square test for categorical variables and Student’s t-test for
continuous variables
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to 30 % in the United States [34, 35]. In Finland, during
2005–2009, 84 % of patients with Alzheimer’s disease
used AChEI and 47 % memantine, 22 % using both of
these concomitantly [36]. In our study, donepezil was
the most commonly used anti-dementia drug, consistent
with previous studies [36]. The use of memantine or
combination therapy was common also in our study,
whereas in Sweden, memantine was used in 2007 by
only 3.1 % of patients with cognitive impairment [26].
The main strength of our study is the nearly 100 %
coverage of the targeted study population, receiving
long-term residential care or regular home care services
in the South Savo Hospital District. We obtained com-
prehensive data concerning drug use, NPS profile and
basic demographic characteristics of these patients, en-
abling a representative overview of the use of anti-
dementia drugs and NPS in two different care settings.
The study has also some limitations. We did not ask the
dates of dementia diagnosis, start of the anti-dementia
drugs or the beginning of NPS. This cross-sectional de-
sign forms a limitation, and allows us only to evaluate
the correlations between NPS and use of anti-dementia
drugs at a spesific time point. The questionnaires also
gave only an approximation of NPS, as the interrater re-
liability was not assessed, and nurses had only written
instructions for evaluating the symptoms of patients.
The assessment of only the presence or absence of the
symptom forms a limitation. Different time windows to
detect NPS in home care and residential care (previous
week vs. preceding 24 h) due to different observational
possibilities may also have affected the prevalence of
NPS to some extent. However, there are only a few
Table 4 Frequency of NPS and subgroups, ADL functioning and cognition by use of anti-dementia drugs
AChEI only Memantine only AChEI and memantine P-value*
n = 465 n = 145 n = 181
Frequency of NPS, n (%)
None 202 (43.4) 60 (41.4) 58 (32.0) 0.065
One symptom 144 (31.0) 47 (32.4) 61 (33.7) 0.569
Two to three symptoms 97 (20.9) 28 (19.3) 46 (25.4) 0.296
Four or more symptoms 22 (4.7) 10 (6.9) 16 (8.8) 0.107
Any NPD, n (%) 263 (56.6) 85 (58.6) 123 (68.0) 0.029
Subgroups, n (%)
Hyperactivity 136 (29.2) 45 (31.0) 83 (45.9)
Psychosis 54 (11.6) 18 (12.4) 33 (18.2)
Mood symptoms and apathy 170 (36.6) 57 (39.3) 72 (39.8)
ADL score, mean (SD) 62.3 (31.5) 48.0 (31.7) 54.6 (28.9) <0.001
MMSE, mean (SD) 17.2 (6.3) 14.4 (7.2) 13.9 (6.2) <0.001
ADL = Barthel Index, scale 0–100
NPS Neuropsychiatric symptoms, AChEI Acetylcholinesterase inhibitor, MMSE Mini Mental State Examination
*Chi-square test for categorical variables and one-way analysis of variance for continuous variables
Table 5 Univariate and multivariate associations between patient characteristics, subgroups and anti-dementia drug use
Variable AChEI only Memantine only AChEI + memantine
Univariate Multivariatea Univariate Multivariatea Univariate Multivariatea
OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Age (years) 1.02 (1.00 to 1.04) 1.04 (1.01 to 1.06) 1.03 (1.00 to 1.07) 1.05 (1.02 to 1.08) 0.99 (0.96 to 1.01)
Female sex 1.06 (0.78 to 1.43) 1.48 (0.93 to 2.33) 1.00 (0.67 to 1.48)
ADL score 1.03 (1.02 to 1.03) 1.03 (1.02 to 1.04) 1.01 (1.01 to 1.02) 1.02 (1.01 to 1.03) 1.02 (1.01 to 1.03) 1.02 (1.02 to 1.04)
Residential care 0.31 (0.24 to 0.40) 1.37 (1.04 to 1.80) 1.13 (0.79 to 1.56)
NPS subgroups
Hyperactivity 0.83 (0.61 to 1.12) 0.91 (0.60 to 1.38) 1.69 (1.17 to 2.45) 2.03 (1.36 to 3.04)
Psychosis 1.15 (0.73 to 1.97) 1.24 (0.67 to 2.26) 1.93 (1.16 to 3.23)
Mood symptoms and apathy 1.66 (1.22 to 2.25) 1.44 (1.03 to 2.02) 1.87 (1.24 to 2.83) 1.77 (1.15 to 2.72) 1.91 (1.30 to 2.80) 1.56 (1.03 to 2.34)
ADL score = Barthel Index, scale 0–100
AChEI Acetylcholinesterase inhibitor, NPS Neuropsychiatric symptoms, OR odds ratio, CI confidence interval
aForward selection. Variables included in the multivariate model are shown
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studies about NPS in home-dwelling persons with de-
mentia [37] and there are, to our knowledge, no other
studies detecting NPS in a almost all persons receiving
home care in a defined area.
Conclusions
The use of anti-dementia drugs was common both in
long-term residential care and home care. The use of
AChEI and/or memantine was associated with the mood
and apathy subgroup and combination therapy with the
hyperactivity subgroup symptoms. As clinicians, we need
more studies on the effectiveness of anti-dementia drugs
to ensure effective and safe pharmacotherapy for our
vulnerable patients with dementia.
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